Comparing STRATIFY JCV™ DxSelect™ and IMMUNOWELL™ JCV Tests in RRMS to Assess PML Risk
Compared to the STRATIFY JCV™ DxSelect™, the IMMUNOWELL™ JCV test tends to place more patients in higher risk categories. Further, longitudinal studies are needed to evaluate the clinical impact of these differences in PML risk assessment.
Authors
- Carlo Avolio (ORCID: https://orcid.org/0000-0002-0987-1967)
- Fabiana Marinelli (ORCID: https://orcid.org/0000-0003-4697-2051)
- Aurora Zanghì (ORCID: https://orcid.org/0000-0002-9566-3135)
- Emanuele D’Amico (ORCID: https://orcid.org/0000-0001-7494-9057)
- Paola Sofia Di Filippo
Institutions
- University of Foggia (IT)
Publication Details
- Journal
- Current Neuropharmacology
- Published
- 2025-04-08
- DOI
- https://doi.org/10.2174/011570159x372688250226110925
- Citations
- 2
- Primary Topic
- Polyomavirus and related diseases
- Type
- article
- Field-Weighted Citation Impact
- 2.09